GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Net Change in Cash

Gilead Sciences (BUE:GILD) Net Change in Cash : ARS227,774 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Gilead Sciences's Net Change in Cash for the three months ended in Dec. 2023 was ARS137,180 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was ARS227,774 Mil.

Gilead Sciences Net Change in Cash Historical Data

The historical data trend for Gilead Sciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Net Change in Cash Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -377,111.64 -458,494.90 -66,552.41 12,406.10 242,953.00

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119,534.45 -93,836.25 184,080.00 349.95 137,180.00

Gilead Sciences Net Change in Cash Calculation

Gilead Sciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=2890166.003+-817665.001+-1850125.002+20577
=242,953

Gilead Sciences's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=783009.001+-262447+-396739+13357
=137,180

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS227,774 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BUE:GILD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Net Change in Cash
Comparable Companies
BMY BIIB AMGN PFE OGN AMRN SCLX MIRA ABBV MRK LLY JNJ LSE:AZN XSWX:ROG XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.